R&D Focus

Our mission is to improve lives by creating access to innovative medicines. Our next-generation technology platforms use established clinical stage modalities and incorporate innovative and novel features. This enables us to discover and develop potential therapies against promising targets. 

We are focused on creating differentiated therapeutic molecules with the potential to be first-in-class and best-in-class with the ultimate aim to provide therapeutic benefit for patients. 

Using these platforms, we are progressing our portfolio of novel and differentiated therapies for the treatment of cancer and respiratory diseases. Our diversified pipeline consists of both clinical- and pre-clinical-stage programmes that address the unmet needs of patients globally. Our R&D activities are focused in two areas. In Oncology R&D, we develop immuno-oncology therapies and in Respiratory R&D we develop therapies and delivery devices for respiratory diseases.

Oncology R&D

Our Oncology R&D Team, based in Cambridge, UK, has developed pioneering new immuno-oncology therapeutics based on our proprietary, multi-specific antibody technology. Our pipeline includes three bispecific antibodies in clinical development and multiple additional projects in preclinical development.

More info

Respiratory R&D

In the Respiratory Innovation Centre, we are developing innovative and generic drug-device combination products using a proprietary next-generation soft mist inhaler (SMI) platform, called Softhaler®, with proven superior clinical performance. We have a pipeline of approved products to treat asthma and COPD, and are investigating innovative molecules for other indications.

More info